2022 Recovery Research Summit: Advancing a Recovery-Ready Nation
Global Recovery Initiatives Foundation (GRI) hosted the 2022 Recovery Research Summit: Advancing a Recovery-Ready Nation in partnership with our leading sponsor Fors Marsh Group (FMG) on September 14 and 15, 2022. This invitation-only event was free to attend and was be conducted virtually via Zoom.
Background – GRI convened the inaugural recovery research summit, Assessing Progress and Setting Priorities in Recovery Research, on July 27, 2020. This inaugural gathering brought together more than 200 participants—including recovery researchers, academic institutions, private funders, corporations, and senior government officials from HHS, ONDCP, CDC, SAMHSA, and NIH—to identify gaps, challenges, and opportunities to advance the field of recovery. Key findings and recommendations that came out of the first summit can be found here.
Agenda – This year’s summit addressed emerging topics related to recovery research, aligned with the priorities set forth in the White House’s Office of National Drug Control Policy’s (ONDCP) National Drug Control Strategy, “Building a Recovery-Ready Nation.” ONDCP Director Rahul Gupta opened the conference, and was followed with reports from federal leadership, recently funded recovery research grantees, and other recovery-invested thought leaders.
The summit was organized around three areas of discovery and inquiry:
- Expanding the science of recovery
- Making recovery possible for more Americans
- Eliminating barriers and increasing opportunities (for recovery)
The virtual summit opened on Wednesday, September 14 at 3:00 p.m. with words from Dr. Gupta, director of ONDCP, followed by a fireside chat conducted by senior leaders reflecting on how we have progressed and what is next. Thursday, September 15 included a day of panel discussions addressing the progress made in the field of recovery research and its impact on improving sustained recovery.
The 2022 Recovery Research Summit is chaired by Dr. Andrea Barthwell in her role as a board member of GRI. Summit 2022 Planning Committee members include:
- Andrea Barthwell (chair), GRI, Board Member; ONDCP, former Director of Demand Reaction; American Society of Addiction Medicine (ASAM), former President
- David Best, Recovery Research Institute, Author and Professor
- Carlos Blanco, NIDA, Director of the Division of Epidemiology, Services, and Prevention Research
- Dona Dmitrovic, SAMHSA, Senior Advisor for Recovery
- Matt Escoubas, FMG, Director of Social Impact; GRI, Board Member
- Peter Gaumond, ONDCP, Senior Policy Analyst/Chief, Recovery Branch
- Cathie Hartnett, GRI, Board Member
- Christopher Jones, CDC, Acting Director of the National Center for Injury Prevention and Control
- John Kelly, Recovery Research Institute, Founder and Director; Harvard Medical School, Professor of Psychiatry in Addiction Medicine
- Memi Miscally, FMG, Director of Health Communication Research
- Deidra Roach, NIAAA, Program Director of the Treatment, Health Services, and Recovery Branch
- Karen Scott, FORE, President
GRI would like to thank Fors Marsh Group (FMG) for being the presenting sponsor of Summit 2022.
About FMG: Fors Marsh Group is a research and strategy firm and a certified B Corporation committed to helping people make better decisions. FMG’s Social Impact Division provides pro bono research, marketing, and communications support to nonprofit organizations working to solve pressing societal challenges. FMG leverages its internal resources to support systems change and engage in social impact on the issue of SUD.
FMG has committed to conducting a national multiyear survey to measure public opinion on aspects of SUD related to the workplace. The Workplace Recovery Survey seeks to generate a statistically valid snapshot of Americans’ knowledge, attitudes, and experiences regarding recovery from SUD in the workplace, with an emphasis on employer-based recovery policies, practices, and services. The first results of the survey will be released at Summit 2022.
GRI is grateful for the additional support from FORE and Pear Therapeutics in advancing attention to recovery research.